USA - NASDAQ:AKAN - CA00971M5028 - Common Stock
Taking everything into account, AKAN scores 2 out of 10 in our fundamental rating. AKAN was compared to 196 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AKAN have multiple concerns. AKAN does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -51.76% | ||
ROE | -95.78% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 24.91% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.08 | ||
Debt/FCF | N/A | ||
Altman-Z | -11.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.39 | ||
Quick Ratio | 1.39 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:AKAN (9/26/2025, 8:00:00 PM)
3.88
+0.09 (+2.37%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.39 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.66 | ||
P/tB | 0.66 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -51.76% | ||
ROE | -95.78% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 24.91% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.08 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 1486.96% | ||
Cap/Sales | 250.76% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.39 | ||
Quick Ratio | 1.39 | ||
Altman-Z | -11.2 |